Cultured human cells release soluble gamma-glutamyltransferase complexes corresponding to the plasma b-GGT

Biomarkers. 2009 Nov;14(7):486-92. doi: 10.3109/13547500903093757.

Abstract

Serum gamma-glutamyltransferase (GGT) is thought to derive from the liver, but its values predict morbidity and mortality for several diseases, such as cardiac infarction, stroke, diabetes, renal failure and cancer. We assessed total GGT and its fractions in the culture supernatants of human cell lines (melanoma, prostate cancer, bronchial epithelium) by gel filtration chromatography. We also compared the GGT elution profile in plasma and the corresponding very-low-density lipoprotein (VLDL) fraction. All the cell lines tested released soluble GGT whose activity increased in parallel with the cell growth. Released GGT presented a molecular weight of 2000 kDa, identical to the b-GGT fraction of human plasma and corresponding to that of VLDL. But ultracentrifugation studies showed that b-GGT had a higher density than VLDL. The b-GGT present in human plasma can be produced by tissues other than the liver, thus explaining the increase of serum GGT observed in diseases of other organs.

MeSH terms

  • Biomarkers / blood
  • Biomarkers / metabolism
  • Blotting, Western
  • Cell Line
  • Cell Line, Tumor
  • Chromatography, Gel
  • Humans
  • Lipoproteins, VLDL / blood
  • Liver / enzymology
  • Molecular Weight
  • Solubility
  • Ultracentrifugation
  • gamma-Glutamyltransferase / blood*
  • gamma-Glutamyltransferase / chemistry
  • gamma-Glutamyltransferase / metabolism*

Substances

  • Biomarkers
  • Lipoproteins, VLDL
  • gamma-Glutamyltransferase